About Johnson & Johnson
Johnson & Johnson now focuses on pharmaceuticals (Stelara, Darzalex, Tremfya) and medical devices after spinning off consumer health as Kenvue. Dividend King with 63 years of increases, ~2.1% yield, very low beta (~0.53). Thin premiums outside litigation events — talc lawsuit overhangs and patent cliffs can trigger sharp gap-downs.
Pharmaceuticals